A study published in the journal Frontiers of Medicine has found an association between the inactivated COVID-19 vaccine CoronaVac from Sinovac Biotech and immune thrombotic thrombocytopenic purpura ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports ...

Realities of a 'new frontier' of conflict and changing battlefields have forced the Philippines to retool its defence ...

This report presents two cases of TTP occurring after the administration of the inactivated vaccine CoronaVac from Sinovac ...

Tetanus is a serious bacterial infection caused by Clostridium tetani, which affects the nervous system, leading to muscle stiffness and spasms. With an increased awareness of disease prevention, ...

The Oxford AstraZeneca vaccine is credited with saving millions of lives but it was also responsible, in rare cases, for serious side-effects - blood clots in the brain - which could be fatal.

What You Need to Know About FluMist, the Nasal Flu Vaccine By Robin Foster HealthDay Reporter SATURDAY, Oct. 26, 2024 (HealthDay News) -- Now that the U.S. Food and Drug Administration has ...

Or sign-in if you have an account. An mRNA vaccine, a cousin to the COVID vaccines that blunted the pandemic, has entered human trials as a treatment for lung cancer. BNT116 is a striking example ...

The Bay Area Rapid Transit (BART) employees filed a discrimination lawsuit saying they were wrongly terminated for refusing the vaccine on “sincerely held religious beliefs.” Federal jurors ...

About a week later, the agency authorized an updated version of Novavax’s protein subunit vaccine for people 12 years and older. The mRNA vaccines specifically target KP.2, a subvariant of JN.